A Redfin report projects that US housing costs might return to 2018 'normal' levels within 5 to 10 years, depending on mortgage rates and home price trends. If mortgage rates drop to 6% and home prices grow modestly, costs could normalize in about 5 years. However, if rates stay high around 7-8% and prices continue rising, it could take over a decade. Regions like San Jose and Austin are closest to normalizing soon due to declining prices and strong wage growth, while many Northeast and Midwest metros may face longer timelines due to competitive markets and rising prices. The report advises buyers to focus on personal financial readiness rather than market timing.
U.S. housing costs potentially normalizing within 5 to 10 years provide context for the real estate market snapshot on Pluang. For readers following U.S. real estate stocks, here is Pluang's market snapshot as of Oct 08, 2026 18:12 WIB: Of 26 priced Real Estate-sector U.S. stocks, 6 rose and 18 fell today. Notable prices include PLD (Prologis Inc) at USD 126.44 with a 1-day change of -0.68% and 100% buy order activity, NLY (Annaly Capital Management, Inc.) at USD 17.81 with a 1-day change of -0.67% and 98% buy order activity, and DLR (Digital Realty Trust, Inc.) at USD 179.50 with a 1-day change of -0.54%.
MIND, an AI-native data loss prevention (DLP) platform, was named "Data Loss Prevention Platform of the Year" in the 2026 CyberSecurity Breakthrough Awards. The platform uses advanced AI to discover, detect, and prevent sensitive data leaks across va...
The global Mivan construction market is projected to grow from $3.92 billion in 2025 to $7.05 billion by 2031, at a CAGR of 10.28%. Growth is fueled by demand for rapid mass housing, affordable residential projects, and faster construction enabled by...
RBC Capital has increased its price target for Amgen from $400 to $430, reflecting strong confidence in the biopharmaceutical company's future performance. Amgen's stock has outperformed both the S&P 500 and the broader medical sector recently, suppo...
Tilray Brands reported a wider-than-expected loss of $0.32 per share for Q1 fiscal 2027, missing revenue estimates with $257.1 million, though revenue grew 23% year-over-year. The company achieved record first-quarter gross profit with a 30% gross ma...
UnitedHealth Group is expected to report Q3 earnings of $4.12 per share on $111.3 billion revenue, with investors closely watching medical cost trends and Medicare Advantage membership. The company improved its medical care ratio and operating earnin...
